Search This Blog

Friday, January 10, 2025

Transferring IRA Money to an HSA

 Did you know you can make a one-time, penalty- and tax-free money rollover from your individual retirement account (IRA) to a health savings account (HSA)? The process is officially known as a qualified HSA funding distribution, and it was made possible by the Health Opportunity Patient Empowerment Act in 2006.

1 However, this process stipulates that you must still eligible to contribute to your HSA, and there are also funding limits and other restrictions to keep in mind.2

Key Takeaways

  • HSAs come with out-of-pocket expenses and annual contribution limits, and you must be enrolled in a high-deductible health plan to qualify for one.
  • You can make a one-time distribution of money from your IRA into a health savings account.
  • A testing period requires you to remain eligible for the HSA for at least 12 months after the rollover.
  • You must first roll funds into an IRA before moving them from another type of retirement account, such as a 401(k) or a 457 plan, to an HSA.
  • Contributing to both an HSA and a traditional IRA will lower your adjusted gross income and reduce your taxes.

What Is a Health Savings Account (HSA)?

health savings account (HSA) is designed for people with high-deductible health plans (HDHPs). These are health insurance policies with annual deductibles of at least $1,600 for individuals and $3,200 for family coverage for 2024 ($1,650 and $3,300 in 2025).34

Here are a few key figures you need to know about the HSA:

  • For 2024, the annual maximum out-of-pocket expense must be less than $8,050 for individuals ($8,300 in 2025) and $16,100 for families ($16,600 in 2025).
  • The annual contribution limit for individuals is $4,150 for 2024 ($4,300 for 2025) and $8,300 for families ($8,550 for 2025).

Remember that your premiums don't count as out-of-pocket costs, but deductibles, copayments, and coinsurance do.

You contribute to an HSA using pre-tax funds, which reduces your taxable income. You can then withdraw money from your HSA tax-free if you use it for qualified medical expenses. However, if you're 64 or younger, you'll owe taxes and a 20% penalty if you use funds for non-medical reasons. Withdrawals for non-medical reasons don't incur the penalty after you turn 65 or if you have a disability at any age, although they're still taxed at your current tax rate.


You can keep your HSA funds in the account to use later in life, such as after you retire. The account (and all the money in it) belongs to you, even if you change health insurance plans, switch jobs, or retire.2

You can only make one rollover from an IRA to an HSA during your lifetime.2

IRA-to-HSA Rollover Rules

You can move funds from an IRA to an HSA only if you're eligible to contribute to your HSA. In other words, you need to do the transfer while you're covered by an HDHP and are otherwise qualified to have an HSA.

Moreover, the IRA-to-HSA rollover includes a testing period that requires you to remain eligible for your HSA for 12 months following the transfer. This means you must stay in your HDHP at least until the testing period expires. If you don't remain eligible (for example, you switch to a non-HDHP), you'll need to include the money you rolled over as income when you file your taxes. In addition, the amount will be subject to a 10% penalty.2

You can only roll funds from an IRA to an HSA once during your lifetime. The maximum amount you can roll over is the same as your annual HSA contribution limit for that year.5

The limits for 2024 and 2025 are as follows:324

  • $4,150 ($4,300 for 2025) for individuals, with an additional $1,000 catch-up contribution if you're 55 or older.
  • $8,300 ($8,550 for 2025) for family coverage, with the same $1,000 catch-up contribution.

Keep in mind that HSAs and IRAs are individual accounts. There's no such thing as a joint IRA or a joint HSA. This means that you and your spouse can each roll funds over from your respective IRAs to your own HSAs but not to each other's HSAs if you're married. But you can cover health care expenses for each other and other family members out of either account.2

Rolling into an HSA from a traditional IRA—instead of a Roth—typically offers a better tax benefit.

Rollovers From Other Accounts

Traditional IRAs

You can roll over from a traditional or a Roth IRA to an HSA.2 However, it's more advantageous to roll from a traditional IRA as this account offers you more benefits. That's because withdrawals of contributions from a Roth IRA are already tax and penalty-free at any time, and you can withdraw earnings tax-free after age 59½.6

A rollover from a traditional IRA to an HSA allows you to load your HSA immediately to pay for medical expenses on a tax-free basis. Any nondeductible IRA contributions you make are not eligible for the rollover, so they will remain in your IRA. Since withdrawals from the HSA are tax-free when used for qualified medical expenses, you would see a tax benefit versus a traditional IRA, whereby you would pay income tax on the withdrawn funds.

401(k) and 457 Plans

You may also be able to fund your HSA by rolling over money from other types of retirement accounts, such as a 401(k) or 457 plan. To roll the funds over from other retirement accounts, you must first roll those funds into an IRA. Once the funds are in an IRA, you can make your one-time, tax-free transfer into your HSA.2 This type of move is tricky and should be done with the help of a professional financial advisor.

Other Ways to Fund an HSA

If you can afford to contribute to both your HSA and a traditional IRA, you’ll lower your adjusted gross income (AGI) and reduce your taxes.7 And your IRA will continue to grow for retirement.

If money is tight and you’re 59½ or older, you could take a regular withdrawal from your IRA and use it to contribute to your HSA. The tax bite from the traditional IRA withdrawal and the tax deduction from the HSA contribution should nearly cancel each other out. And most importantly, you can do this more than once—in fact, every year if you want.

Can I Rollover Funds From an IRA to an HSA?

Yes, you can rollover funds from an IRA to your HSA if you're eligible to contribute to the latter.2

Can I Rollover Funds From a 401(k) to an HSA?

Funds cannot be rolled over to an HSA from a 401(k). However, you can roll funds from a 401(k) to an IRA, then roll the IRA over to an HSA.

Should I Put Money in an HSA or IRA?

It depends on your situation. Not everyone qualifies for both, so you may only be able to choose one. If you are eligible for both and can afford to contribute to them, you can contribute to each of them and maximize savings and returns.

The Bottom Line

Health savings accounts (HSAs) offer tax benefits since your contributions reduce your taxable income. HSAs can be used to pay for medical expenses, including copays and prescriptions. However, HSAs have annual contribution limits, and you must be enrolled in a high-deductible health plan to qualify. You can also roll over funds from an IRA into an HSA. Please consult a tax professional to determine if an HSA or transferring your IRA into an HSA is the best financial decision for you.

https://www.investopedia.com/transfer-ira-money-to-an-hsa-4770819

Eli Lilly pushes into pulmonary fibrosis with $99M deal for Mediar's midphase prospect

 Eli Lilly is making a play for the idiopathic pulmonary fibrosis (IPF) market, offering Mediar Therapeutics $99 million in upfront and near-term payments for global rights to an asset that is entering phase 2.

The deal, which includes up to $687 million in milestones, gives Lilly global rights to the anti-WISP1 antibody MTX-463. Researchers have linked WISP1 to fibrosis progression, leading Mediar to identify the protein as a way to reduce scarring in IPF and other diseases driven by the accumulation of scar tissue. Mediar recently finished a phase 1 trial in healthy volunteers.

With the study showing MTX-463 is well tolerated and engages WISP1, Lilly has swooped in to secure an asset that could unlock a market currently dominated by Boehringer Ingelheim’s Ofev and Roche’s Esbriet. Efforts to create next-generation products have largely ended in failure, although Boehringer reported a phase 3 win last year.

Lilly has been an observer as other companies have swung and missed at IPF, but it does have some links to the indication. Endeavor BioMedicines is testing an ex-Lilly molecule in IPF. Morphic once had an IPF collaboration with AbbVie, but the biotech was focused on inflammatory bowel disease by the time Lilly bought it last year.

The Mediar deal establishes Lilly as a player in the IPF space, albeit one that is further from market than some of the other runners and riders. Mediar plans to start a phase 2 trial of MTX-463 in the first half of 2025. The biotech will run the midphase trial and then hand over to Lilly for further development.

Lilly is one of a handful of Big Pharmas that secured a close look at Mediar through venture investments. Bristol Myers Squibb, Lilly, Novartis Venture Fund, Ono Venture Investment and Pfizer Ventures invested in 2023 in the $105 million financing that positioned Mediar to enter the clinic. The funding reflected the potential for Mediar to deliver a first-in-class therapy that more precisely treats IPF than existing drugs.

https://www.fiercebiotech.com/biotech/eli-lilly-pushes-pulmonary-fibrosis-99m-deal-mediars-midphase-prospect

Somatic Tracking for Dummies

 



https://www.bch.org/documents/content/somatic-tracking-exercise.pdf

Walgreens turnaround strategy, sale of VillageMD boosts 2025 Q1

 Walgreens Boots Alliance (WBA) beat Wall Street estimates on its adjusted earnings per share and sales for the first quarter of fiscal year 2025 on Friday, even as questions remain about its future as a public company.

The company reported $39.5 billion in revenue for the quarter, up 7% from the same quarter last quarter and above Bloomberg consensus estimates of $37.3 billion. Walgreens also reported adjusted earnings per share of $0.51, compared to consensus estimates of $0.38 per share.


The company saw lower-than-expected sales of vaccines and over-the-counter flu season medicine, as the winter respiratory virus season has not been as bad as in previous years.

The stock traded higher Friday, up 27% to $11.70 per share, on the news the company is moving ahead with its separation of the VillageMD healthcare services business. Walgreens has pursued a shift in strategy since CEO Tim Wentworth took over in late 2023.


VillageMD has been performing poorly, resulting in an operating loss for Walgreens' books. This quarter it performed slightly better, along with the company's pharmacy benefits manager, Shields. Together, they reported a loss of $325 million, compared to a $436 million loss in the prior period.

The company is still evaluating what to do with New Jersey-based Summit Health and CityMD urgent care centers, which were also part of the VillageMD controlling stake acquisition in 2021.

The company has faced a number of pressures, which spurred a round of store closures amid a tough retail environment. Front-of-store sales have typically been a drag on all retail pharmacies in recent years as customers pivot to shopping online and through other avenues.

Wentworth highlighted some improvements in the store experience, including a digital waiting list for prescription pick-up to help customers avoid taking up pharmacists' time while they are trying to get prescriptions filled.

Wentworth said this would allow customers a chance to shop while they wait. If they do, the customers will face groupings of products; for example, some might focus on women's health. It's a way of meeting customers' needs where they are, he said.

Walgreens is still in the process of closing about 450 low-performing stores, 67 of which were closed as of the first quarter.


https://finance.yahoo.com/news/walgreens-turnaround-strategy-sale-of-villagemd-boosts-2025-q1-182723348.html

Hims & Hers cut to Sell from Neutral by Citi

 Target to $25 from $24

https://finviz.com/quote.ashx?t=HIMS&ty=c&ta=1&p=d

Rhythm Prelim Fourth Quarter and Full Year 2024 Net Product Revenues, Pipeline Advancements

 -- Preliminary unaudited net revenues from global sales of IMCIVREE® (setmelanotide) of approximately $42 million for the fourth quarter of 2024 and approximately $130 million for the full year of 2024 --

-- On track to report topline data from global Phase 3 trial evaluating setmelanotide in acquired hypothalamic obesity in the first half of 2025 --

-- Completed enrollment in supplemental Japanese cohort of Phase 3 trial of setmelanotide in acquired hypothalamic obesity --

-- Completed enrollment in two substudies in Phase 3 EMANATE trial of setmelanotide in genetically-caused MC4R pathway diseases --

-- Plan to initiate new Phase 2 trial exploring setmelanotide in Prader-Willi syndrome --

https://www.globenewswire.com/news-release/2025/01/10/3007577/0/en/Rhythm-Pharmaceuticals-Announces-Preliminary-Fourth-Quarter-and-Full-Year-2024-Net-Product-Revenues-Pipeline-Advancements-and-Upcoming-Milestones.html

Pfizer’s PD-1 drug succeeds; AbbVie writes down $3.5B in Cerevel assets

 Pfizer on Friday said its PD-1 inhibitor sasanlimab, when combined with standard therapy in people with bladder cancer, delayed death and disease complications longer than standard therapy alone. The Phase 3 trial could give Pfizer’s subcutaneous immunotherapy an edge over rival drugs, like Merck & Co.’s Keytruda and Bristol Myers Squibb’s Opdivo, which are approved to treat people with more advanced disease. Pfizer tested sasanlimab with an immunotherapy called Bacillus Calmette-Guérin in people whose cancer hadn’t spread beyond the bladder lining after surgery. If sasanlimab wins Food and Drug Administration approval, it could be the fourth PD-1 or PD-L1 inhibitor cleared as an under-the-skin shot. The FDA has already approved subcutaneous versions of Roche’s Tecentriq and Opdivo, and Merck has positive Phase 3 data in hand for under-the-skin Keytruda. 

AbbVie has recorded an approximately $3.5 billion impairment charge related to its purchase of Cerevel Therapeutics, according to a new financial filing. Through its $8.7 billion acquisition, which completed last summer, AbbVie got a pipeline of experimental brain drugs, including one that looked to be a promising new therapy for schizophrenia. But that drug suffered a major clinical setback late last year. The “outright failure” — as one analyst described it — was so significant that AbbVie subsequently lost more than $40 billion in market value. — Jacob Bell

Royalty Pharma is simplifying its corporate structure, announcing Friday a deal to absorb the management company that’s run Royalty since its founding in 1996. Royalty will acquire RP Management LLC using equity and some $100 million in cash, along with assuming RP Management’s debt. By internalizing RP Management, Royalty will no longer pay it a 6.5% fee and a small cut of the investments it makes. Royalty expects the roughly $1.1 billion in total transaction value will be “more than offset” by cash savings of at least $1.6 billion over the next decade. Royalty Pharma acquires stakes in experimental drugs, buying up rights to future royalties once they are approved.

Eli Lilly has licensed rights to an experimental drug for idiopathy pulmonary fibrosis, announcing Friday a deal with biotechnology company Mediar Therapeutics. The antibody drug, dubbed MTX-463, is set to enter Phase 2 testing later this year, which Mediar will handle. Afterwards, Lilly can lead all further development and marketing, a right for which it is paying Mediar $99 million in upfront and near-term milestone fees. Mediar could receive up to $687 million more in additional milestone payments. MTX-463 targets a protein called WISP1 that’s been linked to fibrosis. 

Barinthus Biotherapeutics on Friday said it would reduce its workforce by 65% after deciding to refocus its research on immunology and inflammation. As part of the changes, Barinthus’ chief operating officer and chief financial officer will step down, and the company will close a site in the U.K. Notably, Barinthus no longer plans to invest in a hepatitis B treatment it was developing and will instead seek a partner for the program. Moving forward, the firm will prioritize a celiac disease drug program that’s expected to deliver Phase 1 data this year. All told, the changes extend Barinthus’ cash runway into 2027. 

Biogen is adding yet another new member to its leadership team, announcing Thursday the appointment of Adam Feire as head of business development and external innovation. Feire most recently held a top position in Novartis' business development unit. His addition is the latest in a string of changes to Biogen's C-suite that have taken place since Christopher Viehbacher, who led Sanofi for six years, took over as CEO in late 2022. In his short time at the helm, Viehbacher has made dealmaking more of a priority for Biogen, as exemplified by the company’s $7.3 billion purchase of Reata Pharmaceuticals and $1.2 billion acquisition of HI-Bio.

Alkeus Pharmaceuticals on Thursday said it plans to submit an approval application to the FDA sometime this year for a Stargardt disease drug it’s developing. The drug, called gildeuretinol acetate, has been tested in several trials, among them an open-label study of people in the earliest stages of the progressive eye disease. New results from that study, summarized by Alkeus Thursday, show two more treated individuals had stable vision over two years post-treatment. Alkeus hopes the treatment can preserve sight. Data from a placebo-controlled study are expected this year.

https://finance.yahoo.com/news/pfizer-pd-1-drug-succeeds-114300500.html